WMWilliam J. Mack

William J. Mack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William J. Mack has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association Between Pituitary Adenoma Excision and Risk of Cerebrovascular Disease and Mortality in Patients With Cushing's Disease: A Propensity Score–Matched Analysis

    by Ryan S. Chung, William Zeng, David J. Cote, Keiko M. Kang, Michelle Lin, Ishan Shah, David Gomez, Jonathan Dallas, Robert G. Briggs, Jonathan Sisti, et al.

    BACKGROUND AND OBJECTIVES: Cushing's disease (CD) is a hypercortisolemic state resulting from an adrenocorticotropic hormone-secreting pituitary adenoma (PA). Cerebrovascular disease (CeVD) is a dangerous sequela of CD, yet few studies have characterized its risk in CD. This study aimed to report the risk of CeVD in CD patients with and without surgical treatment. METHODS: This retrospective multicenter study from the TriNetX database included 20 years of data from 69 healthcare organizations. TriNetX was searched to identify adults in the United States with CD. We used 1:1 propensity score matching (PSM) for demographic characteristics and tobacco use to identify a matched non-CD group. Risk ratios were calculated to identify the risk of CeVD. Among patients with CD, we identified those who underwent PA excision after diagnosis and determined associations with CeVD. We used 1:1 PSM matching for demographic characteristics and comorbidities (hypertension, diabetes mellitus, dyslipidemia) to identify a matched non-PA excision CD group. RESULTS: The CD group (n = 4265) was 78.4% female with a mean age at CD diagnosis of 45.7 years. After PSM, patients with CD had a significantly higher risk of any CeVD (risk ratio [RR] = 1.97, 95% CI: 1.70-2.29), ischemic stroke (RR = 2.35, 95% CI: 1.83-3.01), and hemorrhagic stroke (RR = 1.75, 95% CI: 1.22-2.49). Stratification by sex identified similar associations. One thousand three hundred seventy-seven patients with CD who underwent PA excision were identified after matching. PA excision was associated with lower risk of any CeVD (RR = 0.68, 95% CI: 0.55-0.86, number needed to treat [NNT] = 25.6), ischemic stroke (RR = 0.50, 95% CI: 0.35-0.72, NNT = 33.3), and mortality (RR = 0.52, 95% CI: 0.35-0.77, NNT = 40.0) compared with those who did not have excision. Sensitivity analyses using medication-based proxies for biochemical remission showed similar trends between curative and noncurative resection but were not statistically significant. CONCLUSION: This study demonstrated that patients with CD are at an increased risk of CeVD, including ischemic and hemorrhagic stroke. PA excision for patients with CD may reduce lifetime CeVD risk and mortality.

  • Open Access

    Timing of Middle Meningeal Artery Embolization and Surgery: Analysis of the EMBOLISE Trial

    by Maxim Mokin, Jared Knopman, Jason M. Davies, Ameer E. Hassan, Robert E. Harbaugh, Alexander Khalessi, Jens Fiehler, Elad I. Levy, Bradley A. Gross, Ramesh Grandhi, et al.

    BACKGROUND: The EMBOLISE trial (The Embolization of the Middle Meningeal Artery With Onyx Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma) demonstrated that middle meningeal artery embolization as an adjunct to surgical drainage reduces recurrence of symptomatic subacute and chronic subdural hematomas. We performed a subgroup analysis of the EMBOLISE surgical cohort to determine how the timing of embolization relative to surgery impacted various outcomes. METHODS: We performed a post hoc subgroup analysis to examine the association of the timing of embolization relative to surgery with the primary end point (hematoma reoperation within 90 days), secondary end points (clinical and radiographic outcomes), and safety end points (serious adverse events, neurological death, all-cause death, and stroke). RESULTS: Middle meningeal artery embolization before surgery (embolization-first group) and middle meningeal artery embolization after surgery (surgery-first group) were performed in 107 and 78 patients, respectively. Demographics and baseline clinical characteristics of the 2 groups were similar. The core laboratory confirmed the procedure to be successful in all patients with similar rates of distal penetration of Onyx into middle meningeal artery branches at the end of the embolization procedure in both groups (49.5% and 48.7%, respectively, P >0.99). Six of 103 patients in the embolization-first group (5.8%) and none in the surgery-first group needed reoperation within 90 days (analysis with observed data, P =0.08). Hematoma volumes at 90 and 180 days were similar except for lower hematoma thickness in the surgery-first group (2.3±3.0 mm versus 4.4±5.6 mm, P =0.03) at 180 days. Clinical and safety outcomes at 30, 90, and 180 days were similar. CONCLUSIONS: Performing surgical drainage before embolization in patients with subacute and chronic subdural hematomas may help minimize treatment failures and enhance hematoma resolution. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04402632.

  • Open Access

    Low Brain Levels of Dietary Polyphenols and Their Conjugates: Reassessing Mechanisms of Alzheimer’s Disease Prevention

    by Roshni Sharma, Kristina Shkirkova, William J. Mack, Rayudu Gopalakrishna

    Dietary polyphenols such as quercetin, resveratrol, and (−)-epigallocatechin-3-gallate (EGCG) have shown neuroprotective effects in epidemiologic and experimental studies of Alzheimer’s disease (AD), although clinical evidence remains limited. This review highlights the importance of investigating glucuronide and sulfate conjugates of these polyphenols, as well as their intestinal microbial metabolites, at bioavailable low nanomolar concentrations, particularly those capable of reaching the brain. Although many in vitro studies use micromolar concentrations of aglycones, the relevance of such concentrations to neuroprotection remains uncertain. While polyphenols are redox-sensitive, their direct antioxidant or prooxidant effects may be limited at nanomolar concentrations. Instead, their neuroprotective actions appear to be mediated through high-affinity interactions with molecular targets such as the 67-kDa laminin receptor (67LR). This receptor binds both aglycones and conjugates at low nanomolar concentrations through a peptide G region containing glycosaminoglycan- and palindromic sequence-related motifs. The same region also binds the prion–amyloid-β complex, suggesting that polyphenols may antagonize amyloid-β binding and thereby prevent its neurotoxicity. The peptide G region may also function as a redox sensor. Binding of polyphenols to 67LR activates cAMP signaling and downstream neuroprotective pathways involving CREB, SIRT1, and protein phosphatase 2A. In addition, nanomolar concentrations of resveratrol and quercetin inhibit quinone reductase 2, an enzyme associated with cognitive decline and reported to be elevated in AD. Given their low bioavailability in the brain and their distinct molecular targets, combining multiple polyphenols at low doses may produce additive or synergistic effects, enhance efficacy, and minimize potential toxicity in the prevention of AD.


  • Open Access

    Low Brain Levels of Dietary Polyphenols and Their Conjugates: Reassessing Mechanisms of Alzheimer’s Disease Prevention

    by Roshni Sharma, Kristina Shkirkova, William J. Mack, Rayudu Gopalakrishna

    Dietary polyphenols such as quercetin, resveratrol, and (-)-epigallocatechin-3-gallate (EGCG) have been shown to be neuroprotective in epidemiologic and experimental studies of Alzheimer’s disease (AD), though clinical evidence remains limited. This re-view highlights the importance of studying glucuronide and sulfate conjugates of these polyphenols, as well as their intestinal microbial metabolites, at bioavailable low na-nomolar concentrations, particularly those that can reach the brain. While many in vitro studies use micromolar concentrations of aglycones, their relevance to understanding neuroprotection is debated. Although polyphenols are redox-sensitive, their direct antioxidant or prooxidant roles may be limited at nanomolar levels, and reactive oxidation products have not been detected in tissues. Instead, their neuroprotective effects appear to be mediated by high-affinity interactions with molecular targets, such as the 67-kDa laminin receptor (67LR). This receptor binds both aglycones and conjugates at low na-nomolar concentrations via a peptide G region containing glycosaminoglycan and palindromic sequences. The same region also binds the prion-amyloid-β complex, sug-gesting that polyphenols could antagonize amyloid-β binding and prevent its neurotoxicity. The peptide G region may also act as a redox sensor. Polyphenol binding to 67LR activates cAMP signaling and downstream neuroprotective pathways involving CREB, SIRT1, and protein phosphatase 2A. Additionally, nanomolar concentrations of resveratrol and quercetin inhibit quinone reductase 2, an enzyme linked to cognitive decline and elevated in AD. Given their low bioavailability in the brain and distinct molecular targets, combining multiple polyphenols at low doses may yield additive and synergistic effects, enhance efficacy, and minimize potential toxicity in preventing AD.

  • Open Access

    The Role of Diagnostic Spinal Angiography for Thoracoabdominal Aortic Aneurysms: A Clinical Case Series in Patients Undergoing Staged Complex Endovascular Repairs

    by Michelle Lin, Sarah Sternbach, Keiko Kang, Vincent N. Nguyen, Robert G. Briggs, Anand Kaul, Nadia A. Atai, Joseph Carey, William J. Mack, Sukgu M. Han, et al.

    BACKGROUND AND OBJECTIVES: Spinal cord ischemia affects up to 40% of patients undergoing repair of complex thoracoabdominal aortic aneurysms (TAAAs). Preoperative identification of key segmental spinal artery contributors may guide the design of custom fenestrated graft constructs or extra-anatomic bypass. Despite the high resolution provided by diagnostic spinal angiography, it is infrequently performed. We describe the safety, feasibility, diagnostic, and treatment outcomes for a case series of spinal angiography performed before complex endovascular TAAA repair. METHODS: We retrospectively analyzed data from patients who underwent preoperative spinal angiography before endovascular repair of their aortic aneurysms between July 2022 and December 2023. All patients had previously undergone either open and/or endovascular treatment of their aortic aneurysms. RESULTS: Nine patients (mean age 64.7 ± 9.9 years) underwent spinal angiography before endovascular repair of their TAAA. The anterior spinal artery was identified in 4 (44%) cases and the posterior spinal artery in one (11%) patient. There were no complications attributed to the angiograms. Eight (89%) patients underwent subsequent endovascular aortic repair with one segmental artery (right T11) successfully incorporated into the stent construct. Two (20%) patients had unfavorable branch angles/stenosis at the segmental artery origin for stenting. One (11%) patient had symptomatic postoperative spinal ischemia. CONCLUSION: Diagnostic spinal angiography can safely help identify spinal arterial contributors in complex TAAA patients who have undergone previous aortic intervention. Given improvements in fenestrated endovascular technology and extra-anatomic bypass, there are burgeoning tools to prioritize the preservation of blood flow to the spinal cord in preoperative planning.

  • Open Access

    A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C

    by Abhay Sagare, Youbin Kim, Kassandra Kisler, Ruslan Rust, William J. Mack, José A. Fernández, Berislav V. Zlokovic, John H. Griffin

    Activated protein C (APC) exerts anticoagulant and cytoprotective cell signaling activities. APC’s cell signaling requires protease-activated receptor (PAR) PAR1 and PAR3, and APC’s PAR cleavages generate peptides capable of agonizing biased G-protein coupled receptor (GPCR) cytoprotective signaling, resulting in anti-inflammatory and anti-apoptotic activities and endothelial barrier stabilization. The PAR-sequence-derived 34-residue “G10 peptide” comprising PAR1 residues 47–55 covalently attached by a 10-glycine linker to PAR3 residues 51–65 is an orthosteric/allosteric bivalent GPCR agonist that potently mimics APC’s anti-inflammatory activity and endothelial barrier stabilization activity. The objective of this study was to determine whether the G10 peptide mimics APC’s anti-apoptotic activity using cultured murine neurons challenged by N-methyl-d-aspartate that provokes neuronal apoptosis. In these new studies, the G10 peptide mimicked APC’s anti-apoptotic activity. Thus, the PAR-derived 34-residue G10 peptide mimics APC’s three major cytoprotective activities, namely anti-inflammatory and anti-apoptotic activities and endothelial barrier stabilization. Peptides that agonize GPCRs provide promising and currently approved drugs; e.g., semaglutide and tirzepatide that contain 31 and 39 amino acid residues, respectively. Thus, this new study adds to the rationale for pursuing further studies of the G10 peptide for potential therapeutic value for multiple pathologies where APC or signaling-selective APC variants are therapeutic in preclinical animal studies.


  • Open Access

    In vivo neuroprotection in ischemic stroke by activated protein C requires β-arrestin 2

    by Biao Xiang, Yaoming Wang, Ruslan Rust, Kassandra Kisler, William J. Mack, José A. Fernández, Berislav V. Zlokovic, John H. Griffin


  • Addressing the Evidence Gap in Aneurysmal Subarachnoid Hemorrhage: The Need for a Pragmatic Randomized Trial Platform

    by Hooman Kamel, Jose I. Suarez, E. Sander Connolly, Sepideh Amin-Hanjani, William T. Mack, Sherry Hsiang-Yi Chou, Katharina M. Busl, Colin P. Derdeyn, Neha S. Dangayach, Jordan E. Elm, et al.

    Aneurysmal subarachnoid hemorrhage (aSAH) occurs less often than other stroke types but affects younger patients, imposing a disproportionately high burden of long-term disability. Although management advances have improved outcomes over time, relatively few aSAH treatments have been tested in randomized clinical trials (RCTs). One lesson learned from COVID-19 is that trial platforms can facilitate the efficient execution of multicenter RCTs even in complex diseases during challenging conditions. An aSAH trial platform with standardized eligibility criteria, randomization procedures, and end point definitions would enable the study of multiple targeted interventions in a perpetual manner, with treatments entering and leaving the platform based on predefined decision algorithms. An umbrella institutional review board protocol and clinical trial agreement would allow individual arms to be efficiently added as amendments rather than stand-alone protocols. Standardized case report forms using the National Institutes of Health/National Institute of Neurological Disorders and Stroke common data elements and general protocol standardization across arms would create synergies for data management and monitoring. A Bayesian analysis framework would emphasize frequent interim looks to enable early termination of trial arms for futility, common controls, borrowing of information across arms, and adaptive designs. A protocol development committee would assist investigators and encourage pragmatic designs to maximize generalizability, reduce site burden, and execute trials efficiently and cost-effectively. Despite decades of steady clinical progress in the management of aSAH, poor patient outcomes remain common, and despite the increasing availability of RCT data in other fields, it remains difficult to perform RCTs to guide more effective care for aSAH. The development of a platform for pragmatic RCTs in aSAH would help close the evidence gap between aSAH and other stroke types and improve outcomes for this important disease with its disproportionate public health burden.


  • Open Access

    Persistent Inequities in Intravenous Thrombolysis for Acute Ischemic Stroke in the United States: Results From the Nationwide Inpatient Sample

    by Philip Sun, Ling Zheng, Michelle Lin, Steven Cen, Gmerice Hammond, Karen E. Joynt Maddox, May Kim‐Tenser, Nerses Sanossian, William Mack, Amytis Towfighi

    Background: Despite its approval for acute ischemic stroke >25 years ago, intravenous thrombolysis (IVT) remains underused, with inequities by age, sex, race, ethnicity, and geography. Little is known about IVT rates by insurance status. Methods and Results: We assessed temporal trends from 2002 to 2015 in IVT for acute ischemic stroke in the Nationwide Inpatient Sample using adjusted, survey ‐ weighted logistic regression. We calculated odds ratios for IVT for each category in 2002 to 2008 (period 1) and 2009 to 2015 (period 2). IVT use for acute ischemic stroke increased from 1.0% in 2002 to 6.8% in 2015 (adjusted annual relative ratio, 1.15). Individuals aged ≥85 years had the most pronounced increase during 2002 to 2015 (adjusted annual relative ratio, 1.18) but were less likely to receive IVT compared with 18‐ to 44‐year‐olds in period 1 (adjusted odds ratio [aOR], 0.23) and period 2 (aOR, 0.36). Women were less likely than men to receive IVT, but the disparity narrowed over time (period 1: aOR, 0.81; period 2: aOR, 0.94). Inequities in IVT resolved for Hispanic individuals in period 2 (aOR, 0.96) but not for Black individuals (period 2: aOR, 0.81). The disparity in IVT for Medicare patients, compared with privately insured patients, lessened over time (period 1: aOR, 0.59; period 2: aOR, 0.75). Patients treated in rural hospitals remained less likely to receive IVT than in urban hospitals; a more dramatic increase in urbanity widened the inequity (period 2, urban nonteaching versus rural: aOR, 2.58, period 2, urban teaching versus rural: aOR, 3.90). Conclusions: IVT for acute ischemic stroke increased among adults. Despite some encouraging trends, the remaining disparities highlight the need for intensified efforts at addressing inequities.